November 23, 11:29 AM
Centogene (NASDAQ:CNTG) is set to give its latest quarterly earnings report on Wednesday, 2021-11-24. Here's what investors need to know before the announcement. Analysts estimate that Centogene will likely report an Earnings Per Share (EPS) of $-0.55.
The Week Ahead In Biotech (Nov. 21-Nov. 27): Takeda, Aadi, Fennec FDA Decisions, Earnings In The Spotlight In Holiday-Shortened Week
November 21, 4:04 PM
Biotech stocks showed a lack of direction in the week ending Nov. 19 before finishing modestly higher. Stocks did not have much meaningful catalysts to react to amid the winding down of the reporting season and ahead of the holiday week.
Centogene, Twist Bioscience Report Contract To Collab On Development, Commercialization Of Custom Assay Kits For Rare Diseases, No Terms Disclosed
October 6, 8:06 AM
Centogene N.V. (NASDAQ:CNTG), a commercial-stage Company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, and Twist Bioscience Corporation (NASDAQ:TWST), a Company enabling
Centogene Q2 Revenues €51.9M, Up 434% YoY; Commercial OVID-19 Testing Revenues €42.3M, Up From €2.1M YoY
September 7, 6:29 AM
Revenues of €51.9 million in Q2 2021, a 434% increase compared to €9.7 million in Q2 2020; Revenues from the Company’s Pharma and Diagnostics segments (“Core
The Week Ahead In Biotech (Sept. 5-11): Focus On Conferences and Clinical Readouts In Another Quiet Week
September 5, 1:14 PM
Biotech stocks extended their gains in the week ending Sept. 3, partly aided by the broader market strength. The news flow was fairly light ahead of the Labor Day holiday weekend.
June 25, 6:33 AM
Centogene N.V. (NASDAQ:CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, today announced the voting results of the Company’s Annual
June 22, 6:32 AM
Company outlines significant value creation potential to contribute to the diagnosis of rare diseases and to enable the development of novel therapeutics Focuses on leveraging its unique rare disease-centric